Are you Dr. Little?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 10 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9609 Medical Center Dr
Room 5w426
Bethesda, MD 20892Phone+1 240-276-6093Fax+1 240-276-7892
Summary
- Dr. Richard Little, MD is an oncologist in Bethesda, Maryland. He is currently licensed to practice medicine in Virginia.
Education & Training
- University of South Carolina School of MedicineClass of 1989, MD
Certifications & Licensure
- VA State Medical License 1992 - 2024
Publications & Presentations
PubMed
- 11 citationsImplementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials.Andrea M Denicoff, S Percy Ivy, Tami T Tamashiro, Jinxiu Zhao, Katherine H Worthington
Journal of the National Cancer Institute. 2022-11-14 - 148 citationsMolecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T. Flaherty, Robert Gray, Alice P. Chen, Shuli Li, Lisa M. McShane
Journal of Clinical Oncology. 2020-10-13 - 61 citationsPrevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology PracticesScott D. Ramsey, Joseph M. Unger, Laurence H. Baker, Richard F. Little, Rohit Loomba
JAMA Oncology. 2019-04-01
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
Press Mentions
- NIH Launches Precision Medicine Trial for Myeloid CancersOctober 24th, 2024
- NIH Launches myeloMATCH Precision Medicine Trials for Myeloid CancersOctober 23rd, 2024
- NIH Clinical Trial Will Test Precision Medicine Treatments for Myeloid CancersOctober 23rd, 2024
- Join now to see all